DelveInsight’s X-Linked Retinitis Pigmentosa (XLRP) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into X-linked Retinitis Pigmentosa (XLRP) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward.
Some of the key highlights from the X-Linked Retinitis Pigmentosa (XLRP) Market Insights:
- According to a study conducted by Ferrari et al. (2011), retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000–7000 people, and out of estimated percentages of RP types, there are 10–15% X-linked RP cases.
- Some of the key companies profiled in the X-Linked Retinitis Pigmentosa therapeutics domain include Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, Applied Genetic Technologies, and others.
- The dynamics of the X-Linked Retinitis Pigmentosa (XLRP) Market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world and the expected launch of emerging therapies during the forecast period.
- Of the emerging therapies, the most anticipated product to get approval is the gene therapy AAV-RPGR and NSR-RPGR.
- AAV-RPGR a product being jointly developed by MeiraGTx Limited and Janssen Pharmaceuticals, it has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA), and PRIME, ATMP, and Orphan designations by the European Medicines Agency (EMA).
- With many players actively engaged in the therapeutics development, the pipeline for X-Linked Retinitis Pigmentosa (XLRP) brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market for a study period 2018–2030.
Learn more by requesting for sample @ X-Linked Retinitis Pigmentosa (XLRP) Market Landscape
X-Linked Retinitis Pigmentosa (XLRP): Overview
X-linked Retinitis Pigmentosa is an inherited condition that leads to progressive vision loss predominantly in males. The condition begins with night blindness and can cause total loss of vision. According to DelveInsight’s analysis, males are more affected as compared to females, in the case of X-linked Retinitis Pigmentosa. As per the study by Prokisch et al. (2007), “the real prevalence of XLRP affected males was approximately 1:15,000. The cumulated life risk of development of XLRP in carriers was strongly age-dependent and included one-third of the carriers older than 60 years”.
For more insights into Disease, causes, and treatment, reach out @ X-Linked Retinitis Pigmentosa (XLRP) Treatment Landscape
X-Linked Retinitis Pigmentosa (XLRP) Epidemiology Segmentation
The X-Linked Retinitis Pigmentosa (XLRP) Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Prevalent Cases of Retinitis Pigmentosa
- Diagnosed Prevalent Cases of X-linked Retinitis Pigmentosa
- Treatable Cases of X-linked Retinitis Pigmentosa
Visit for more @ X-Linked Retinitis Pigmentosa (XLRP) Epidemiological Insights
X-Linked Retinitis Pigmentosa (XLRP) Market
XLRP is an inherited condition and currently, there is no specific treatment. However, off-label therapies have been observed to provide a positive response in the treatment of patients with XLRP. Some of the therapeutics options such as the administration of vitamin A palmitate, lutein, calcium-channel blockers, and docosohexanoic acid can potentially preserve the photoreceptor function.
To provide an effective therapeutics solution companies worldwide are diligently working towards the development of new therapies and also exploring the possibilities of gene therapies for the XLRP. The expected launch of different gene therapies is expected to provide new dimensions to the XLRP treatment.
X-Linked Retinitis Pigmentosa (XLRP) Pipeline Therapies and Key Companies
- BIIB112 (NSR-RPGR) – Biogen
- AAV-RPGR – MeiraGTx Limited/Janssen Pharmaceuticals
- AGTC-501 (rAAV2tYF-GRK1-RPGR) – Applied Genetic Technologies
For more information, visit X-Linked Retinitis Pigmentosa (XLRP) Market Analysis, Patient Pool, and Emerging Therapies
X-Linked Retinitis Pigmentosa (XLRP) Market Drivers
- Increase in the patient population
- Expected launch of emerging therapies
- Improvement in healthcare spending
Scope of the Report
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of X-Linked Retinitis Pigmentosa (XLRP), covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight into X-Linked Retinitis Pigmentosa (XLRP) epidemiology and treatment in the 7MM
- Current and emerging therapies for X-Linked Retinitis Pigmentosa (XLRP)
- X-Linked Retinitis Pigmentosa (XLRP) market drivers and barriers
Key Questions Answered in the Report
- What was the X-Linked Retinitis Pigmentosa (XLRP) market share (%) distribution in 2018 and how it would look like in 2030?
- What would be the X-Linked Retinitis Pigmentosa (XLRP) total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest X-Linked Retinitis Pigmentosa (XLRP) market size during the forecast period (2018-2030)?
- At what CAGR, the X-Linked Retinitis Pigmentosa (XLRP) market is expected to grow in 7MM during the forecast period (2018-2030)?
Get in touch with our Business executive @ X-Linked Retinitis Pigmentosa (XLRP) Market Landscape Analysis
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction |
| 3 | Competitive Intelligence Analysis for X-Linked Retinitis Pigmentosa (XLRP) |
| 4 | X-Linked Retinitis Pigmentosa (XLRP) Market Overview at a Glance |
| 5 | Executive Summary of X-Linked Retinitis Pigmentosa (XLRP) |
| 6 | X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Market Methodology |
| 7 | X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Patient Population |
| 8 | X-Linked Retinitis Pigmentosa (XLRP) Patient Journey |
| 9 | Treatment Algorithm, Current Treatment, and Medical Practices |
| 10 | Key Endpoints in X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials |
| 11 | X-Linked Retinitis Pigmentosa (XLRP) Marketed Therapies |
| 12 | X-Linked Retinitis Pigmentosa (XLRP) Emerging Therapies |
| 13 | X-Linked Retinitis Pigmentosa (XLRP): 7 Major Market Analysis |
| 14 | Attribute analysis |
| 15 | Access and Reimbursement Overview of X-Linked Retinitis Pigmentosa (XLRP) |
| 16 | KOL Reviews |
| 17 | Case Reports |
| 18 | X-Linked Retinitis Pigmentosa (XLRP) Market Drivers |
| 19 | X-Linked Retinitis Pigmentosa (XLRP) Market Barriers |
| 20 | SWOT Analysis |
| 21 | Disclaimer |
| 22 | DelveInsight Capabilities |
| 23 | About DelveInsight |
Learn more about the report offerings @ X-Linked Retinitis Pigmentosa (XLRP) Market Outlook
Related Reports –
X-linked Retinitis Pigmentosa Pipeline Insight
X-linked Retinitis Pigmentosa Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the X-linked Retinitis Pigmentosa market.
Corneal Endothelial Dystrophy Market
DelveInsight’s “Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Electroencephelographs (EEG) Pipeline Insight
DelveInsight’s, “Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market.
Lymphatic Malformations Market
DelveInsight’s “Lymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lymphatic Malformations market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab– Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Acute Pyelonephritis Market
DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
- JAK inhibitors Pipeline
- Diabetic Macular Edema Market Developments
- Implantable Cardiac Monitors Market Growth
- Neurovascular Thrombectomy Devices Market
- Vagus Nerve Stimulator Market Share
- Wearable Technology Advantages and Disadvantages
- Age-Related Hearing Loss Devices Market
- Impact of Technology on People with Autism
- Common Eye Diseases and Treatments
- Leading Medtech Companies
- Key Companies in the Presbyopia Market
- Spinal Stenosis Devices Market Share
- Bone Cancer Therapeutics Market
- Cardiac Monitoring Devices Market
- Pharma Companies in Skin Cancer Market
Get in touch with our Business executive for Competitive Intelligence Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Information:
Shruti Thakur info@delveinsight.com +91-9650213330
The post X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies – Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies appeared first on Financial Market Brief.